Advicenne announced that it has signed an exclusive distribution agreement with Taïba Healthcare (Taïba), for the commercialization of Sibnayal® in selected Middle-East countries (Kingdom of Saudi Arabia, United Arab of Emirates, Sultanate of Oman, Kuwait, Qatar and Bahrain). The partnership with Taïba is the first Advicenne has signed for Sibnayal® outside of Europe. Under the terms of the agreement, Taiba has exclusive marketing rights to Sibnayal® in its indication of the territories defined in the contract.

In return, Advicenne will receive the proceeds from the sale of Sibnayal® in the form of a transfer price and royalties for a combined amount significantly greater than 50% of future sales. Taiba is currently working on an early access program for Sibnayal® in the contract territories. Taïba and Advicenne will be responsible for the registration of products locally based on the registration dossier file that enabled the marketing authorization in Europe and the United Kingdom.

Following recent collaboration agreements with TwinPharma, ExCEEd Orphan and Frost Pharma in Europe, Advicenne is continuing to make its drug Sibnayal® as widely available as possible.